FitLife Brands develops and markets nutritional supplements and wellness products, offering more than 500 items online and through retail partners under brands including MusclePharm, Irwin Naturals, and Dr. Tobias. The third quarter 2026 results carry added significance as the company continues to integrate its August 2025 acquisition of Irwin Naturals, which altered its revenue composition and increased cost complexity. From what I see, investors are monitoring whether the acquired brands can support profitable expansion while legacy operations encounter challenges such as softer traffic for MRC on Amazon and softness in specialty retail. Management noted a cautious consumer setting and higher input costs, making this report a useful indicator of near-term performance and the sustainability of recent revenue increases. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
For the third quarter ended September 30, 2026, FitLife Brands recorded revenue of $25.6 million, a 9% rise from $23.5 million in the same period a year earlier. Net income increased to $1.6 million from $0.9 million, and diluted EPS reached $0.16, compared with $0.09 previously. Although these figures showed year-over-year progress, they fell short of analyst projections, which centered on roughly $27.9 million in revenue and $0.25 in diluted EPS.
Gross margin edged up to 37.7% from 37.2%, while adjusted EBITDA declined to $3.3 million from $3.8 million. Online revenue expanded 15% to $11.8 million, accounting for 46% of total sales. Over the trailing twelve months, the company reported revenue of $103.4 million and adjusted EBITDA of $13.7 million. Management linked the softer revenue to a weak consumer backdrop, pressure on MRC’s Amazon listings, and lower sales to certain retail partners such as GNC.
Shares of FitLife Brands declined sharply after the release, as the shortfalls relative to consensus overshadowed the year-over-year improvements. This reaction underscores the stock’s sensitivity to indications of slowing growth and margin pressure. Sentiment ahead of the report had already been measured because of the soft consumer environment, and the missed estimates heightened concerns about Irwin Naturals integration and the resilience of established brands. Even with gross margin holding steady and a restructuring plan in place, the market focused on the weaker top line and the drop in adjusted EBITDA.
Several factors deserve attention in the periods ahead. Management’s restructuring, which included about $0.3 million in expenses during the quarter, is projected to lower annual operating costs by approximately $1.2 million starting in the fourth quarter of 2026. Execution on those savings and their impact on profitability will be worth tracking.
The cost environment remains relevant as well. Management highlighted rising prices for whey protein and fish oil and noted that it has secured fixed-price supply for most fish oil needs over the next year or so. These steps could help protect margins near term but may also affect cash flow and working capital.
Brand performance shows variation. Irwin and MusclePharm achieved record online sales in the quarter, while MRC and the specialty retail channel stayed soft. It will be important to see whether the stronger brands can counter ongoing weakness elsewhere and whether the shift toward Amazon-focused distribution for Irwin supports better profitability over time.
Balance sheet management stays pertinent, with the company ending the quarter at about $39.3 million in debt, up modestly from the prior period due to temporary working-capital movements. Watching debt reduction and cash generation will matter as FitLife Brands seeks to stabilize results amid a challenging consumer climate.
When analyzing earnings reports like this one, I often rely on Tickeron’s AI Screener to quickly filter peers and spot comparable patterns in the nutritional supplements space. The tool lets me apply technical, fundamental, and volatility filters to narrow thousands of stocks and ETFs into a focused list, helping surface relevant trade ideas without manual effort. In my view, it serves as a practical addition to traditional review when evaluating how companies like FitLife Brands stack up against industry trends.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Indicator for FTLF moved into overbought territory on November 16, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Following a +3.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where FTLF advanced for three days, in 140 of 211 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
FTLF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 48 cases where FTLF's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 73%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FTLF as a result. In 78 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for FTLF turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 38 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTLF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
The Aroon Indicator for FTLF entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.580) is normal, around the industry mean (6.914). P/E Ratio (11.896) is within average values for comparable stocks, (7.137). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (8.458). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.922) is also within normal values, averaging (5.003).
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. FTLF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FTLF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry FoodMajorDiversified